Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China

Abstract Background To investigate the treatment pattern, adverse events, and quality of life of Chinese patients treated with CDK4/6 inhibitors (CDK4/6i) for hormone receptor (HR)+/HER2- advanced breast cancer. Methods This multicenter cross-sectional survey enrolled patients with HR+/HER2- advance...

Cur síos iomlán

Sonraí bibleagrafaíochta

Príomhchruthaitheoirí:	Benlong Yang, Zhengkui Sun, Quchang Ouyang, Zhongsheng Tong, Shu Wang, Hongyuan Li, Zhaofeng Niu, Yiding Chen, Lin-xiaoxi Ma, Haoqi Wang, Mu Tang, Zheyu Hu, Xueqiang Gao, Xu Wang, Fei Xie, Qiao Cheng, Yong Shen, Cuizhi Geng, Haibo Wang, Jiong Wu
Formáid:	Artigo
Teanga:	Inglês
Foilsithe / Cruthaithe:	BMC 2025-05-01
Sraith:	BMC Cancer
Ábhair:	Abemaciclib Advanced breast cancer Dalpiciclib Palbociclib Ribociclib
Rochtain ar líne:	https://doi.org/10.1186/s12885-025-14223-8
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!